Change Visitor Type Sign up to our newsletter

Strong Start To 2014 For Oxford Capital’s Growth Investment Team

Strong Start To 2014 For Oxford Capital’s Growth Investment Team

By Oxford Capital |

Oxford Capital has delivered a strong start to 2014. It has committed over £20 million to growth capital investments in the year to date, investing alongside leading international venture capitalists. This makes it one of the UK’s most active backers of fast-growing UK enterprises.

David Mott, Managing Partner, Oxford Capital, said:

“Oxford Capital has really moved up a gear in 2014. We are regularly leading investment rounds alongside international venture capital firms, strategic investors and family offices. We believe our strength in fundraising and exceptional pipeline of high quality investment opportunities makes us stand out in the UK growth capital sector. Our rate of UK fundraising and investment so far this year matches or even exceeds that of some of the big name international VC firms.”

Oxford Capital’s growth capital highlights of 2014 to date include investments in:

  • Linkdex – led a US$4 funding round for award-winning ‘organic marketing’ platform provider.
  • Outplay – led a US$5m investment in Dundee-based mobile games developer.
  • Arkivum – led an investment round of up to £1.9m for large-scale digital archiving solutions provider.
  • Intent HQ – led a £4.75m funding round for London-based online audience intelligence provider.
  • BioMonde – backed established profitable wound care business, in a £3.5m funding round.

In addition, the firm has led follow-on investments in existing portfolio companies MirriAd and Cognia.

The investments follow Oxford Capital’s successful growth capital fundraising in recent months. Investors have committed growth capital though the firm’s evergreen Gateway Funds. They have also joined through the Co-Investment Circle which enables family offices and high net worth individuals to invest alongside Oxford Capital, benefiting from its research and access to deals.

A series of successful exits in 2013 has underpinned Oxford Capital’s record start to 2014. It delivered up to 4.7x growth in 2013, though the sale of Arieso, Sirigen and Scancell.

“We back companies which have strong track records of growth. We look for UK firms with proven business models and exceptional management teams. Our approach helps them to thrive and achieve commercial success on the international stage.

“Our focus is broad. We are attracted by the growth opportunities of the digital sector. There are also exciting opportunities in the healthcare and agri-tech sectors. We continue to search for exceptional opportunities and will make more new investments in 2014 and beyond.

“Above all, our approach is one of partnership, with other VCs as well as with entrepreneurs.”

Important information:

  • An investment should only be made on the basis of the formal Information Pack of each fund.
  • Your capital is at risk and you should not invest if you are not willing to bear this risk.
  • Tax advantages are summarised based on current legislation, which may be subject to change in the future.

Awards

  • BEST EIS
    FUND MANAGER
    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR
    WINNER 2013 AND 2005

  • MOST IMPACTFUL
    INVESTMENT
    WINNER 2017

  • BEST ANGEL
    SYNDICATE
    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY
    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS
    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH
    2020

  •            

    EXIT OF THE YEAR 2021 (FINALIST)UK BAA AWARDS